Inflammation is a protective reaction of the human immune system. The inflammatory response is marked by white blood cell migration from the blood stream to the site of inflammation, known as the leukocyte adhesion cascade. In the case of diseases such as asthma, arthritis, COPD, and inflammatory bowel disease, the inflammatory response becomes exaggerated, thus damaging healthy tissue.

LigoCyte develops therapeutic drugs that target binding events in the leukocyte adhesion cascade. By disrupting these events of leukocyte adhesion and migration into tissues, inflammation can be curtailed, restoring the protective inflammatory response to normal. This therapeutic approach holds the potential to halt disease progression, setting it apart from conventional therapies that address symptoms of disease alone.